GLP‐1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis including the REWIND and PIONEER 6 trials

Dario Giugliano,Maria Ida Maiorino,Giuseppe Bellastella,Miriam Longo,Paolo Chiodini,Katherine Esposito

DOI: https://doi.org/10.1111/dom.13847

2019-08-28

Diabetes, Obesity and Metabolism

Abstract:A meta‐analysis is presented of cardiovascular outcome trials (CVOTs) comparing glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) versus placebo on cardiorenal outcomes in patients with type 2 diabetes (T2D). We did an electronic search without language restrictions up to June 15, 2019, for eligible trials. We did a meta‐analysis of available trial data using a random‐effects model to calculate overall hazard ratios (HRs) and 95% CI (confidence intervals). We included data from 7 CVOTs and 56 004 patients (68·9% with established cardiovascular disease). GLP‐1RA reduced major cardiovascular events (MACE) by 13% (HR = 0.87, 95% CI 0.80‐0.96, P = 0.011) with a non‐significant heterogeneity between subgroups of patients with and without cardiovascular disease (CVD) (P = 0.220). GLP‐1RA also reduced the risk cardiovascular death by 12%, nonfatal stroke by 16%, hospitalisation for heart failure by 9%, all‐cause mortality by 11%, and the broad composite kidney outcome by 17%; the latter appeared to be driven by a reduction in macroalbuminuria only (HR = 0.76, 0.68‐0.86, P = 0.003). GLP‐1RA have moderate benefits on MACE, and also reduce hospitalisation for heart failure and all‐cause mortality; they also have robust benefits on reducing the incidence of macroalbuminuria, without affecting the progression of diabetic renal disease.This article is protected by copyright. All rights reserved.